Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03854903
Title WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Georgetown University

Her2-receptor negative breast cancer


Bosutinib + Palbociclib

Bosutinib + Fulvestrant + Palbociclib

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.